Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Thomas PowlesBegoña P ValderramaShilpa GuptaJens BedkeEiji KikuchiJean Hoffman-CensitsGopa IyerChristof VulstekeSe Hoon ParkSang Joon ShinDaniel CastellanoGiuseppe FornariniJian-Ri LiMahmut GümüşNataliya MarYohann LoriotAude FléchonIgnacio DuranAlexandra DrakakiSujata NarayananXuesong YuSeema GorlaBlanca Homet MorenoMichiel S van der Heijdennull nullPublished in: The New England journal of medicine (2024)
Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
Keyphrases
- locally advanced
- squamous cell carcinoma
- hodgkin lymphoma
- rectal cancer
- advanced non small cell lung cancer
- neoadjuvant chemotherapy
- radiation therapy
- phase ii study
- small cell lung cancer
- high grade
- epidermal growth factor receptor
- adverse drug
- emergency department
- lymph node
- adipose tissue
- open label
- glycemic control